Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 7;72(12):2132–2140. doi: 10.1093/cid/ciaa387

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 6. — Relationship of engraftment of SER-109 species to dose administered in the phase 1 and phase 2 studies. Subjects receiving the high dose, as defined by SporQ (see Methods), in the open-label phase 1 dose-ranging study (SERES- 001) had significantly more SER-109 species than subjects in the treatment arm of the phase 2 study (SERES-004), who received a fixed dose (wk1; P < .0001, Mann-Whitney U test). The number of SER-109 species was not significantly different between subjects receiving the low dose in the phase 1 trial and subjects receiving the fixed dose in the phase 2 trial (Mann-Whitney U test). The number of SER-109 species stratified by treatment and time point is shown; dots represent outliers. Sample sizes are shown below the x axis. ***P < .0001. Abbreviations: BL, baseline; ns, nonsignificant; wk1, week 1.